Teva Pharmaceutical Industries Ltd.’s earnings next year will miss analyst estimates if regulators allow generic copies of the multiple-sclerosis drug that brings in more than half the company’s annual profit.
The suffering and costs of dementia would be reduced by preventative measures if the Group of Eight nations adopt a model that has worked in fighting heart disease, a group of doctors and scientists said.
Boehringer Ingelheim GmbH, the German family-owned drugmaker, withheld or failed to preserve “countless” numbers of files sought by patients suing over the company’s blood thinner Pradaxa and must pay a fine of almost $1 million, a judge ruled.
The U.S. Supreme Court left intact a $142 million award against Pfizer Inc. and let two similar suits go forward with claims that the drugmaker defrauded insurers by illegally marketing its Neurontin epilepsy drug.
New medicines from Gilead Sciences Inc., Roche Holding AG, Pharmacyclics Inc. and others are poised to reshape treatment of the most common form of leukemia among adults, potentially eliminating chemotherapy from regimens and extending patients’ lives.
Judy Doetterl was a sales representative for Johnson & Johnson in 2004 when federal agents placed a hidden recording device on her and sent her to tape marketing presentations at a national company sales meeting.
Boston Scientific Corp.’s Watchman device to prevent strokes may face a contentious regulatory meeting this week after a U.S. report showed the surgery required to implant the product may reduce its effectiveness.